| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Pituitary Research Unit (M.B., K.-C.L., K.K.Y.H.) and Neurobiology Research Program (T.P.I.), Garvan Institute of Medical Research, St. Vincents Hospital, Sydney New South Wales 2010, Australia; and Department of Medicine, Clinical Sciences Center (R.J.M.R.), Sheffield University, Sheffield S5 7AU, United Kingdom
Address all correspondence and requests for reprints to: Dr. Ken K. Y. Ho, Pituitary Research Unit, Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia. E-mail: k.ho{at}garvan.unsw.edu.au
Two alternatively spliced exon 9 variants of human GH receptor (GHR) messenger ribonucleic acid (mRNA), GHR-(1279) and GHR-(1277), were recently identified in liver. They encode receptor proteins lacking most of the intracellular domain and inhibit GH action in a dominant negative manner. Little is known about tissue distribution and abundance of these GHR isoforms. We have developed quantitative RT-PCR assays specific for the full-length and truncated GHRs and investigated their expression in various human tissues and cell lines.
The mRNA of full-length GHR and GHR-(1279) were readily detectable in all tissues investigated, with liver, fat, muscle, and kidney showing high levels of expression. These two receptor isoforms were also detected in a range of human cell lines, with strongest expression in IM9, a lymphoblastoid cell line. In contrast, GHR-(1277) message was expressed at low levels in liver, fat, muscle, kidney, and prostate and in trace amount in IM9 cells.
Full-length GHR was the most abundant isoform, accounting for over 90% of total receptor transcripts in liver, fat, and muscle for quantitative RT-PCR. However, liver had 2- to 4-fold more full-length receptor mRNA and 16- to 40-fold more GHR-(1277) mRNA than fat and muscle, whereas the mRNA levels of GHR-(1279) were similar in the three tissues. GHR-(1279) constituted less than 4% in liver and 710% in fat and muscle. GHR-(1277) accounted for 0.5% of total GHR transcripts in liver and less than 0.1% in the other two tissues. These data suggest that the absolute and relative abundance of mRNA of the three GHR isoforms may be tissue specific. The regulation of expression of exon 9 alternatively spliced GHR variants may provide a potential mechanism for modulation of GH sensitivity at the tissue level.
This article has been cited by other articles:
![]() |
A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kenth, J. A M. Mergelas, and C. G. Goodyer Developmental changes in the human GH receptor and its signal transduction pathways J. Endocrinol., July 1, 2008; 198(1): 71 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Swanson and J. J. Kopchick Nuclear Localization of Growth Hormone Receptor: Another Age of Discovery for Cytokine Action? Sci. Signal., December 4, 2007; 2007(415): pe69 - pe69. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Kaplan and P. Cohen REVIEW: The Somatomedin Hypothesis 2007: 50 Years Later J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4529 - 4535. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Bowles, I. Wilkinson, R. A. G. Smith, A. J. G. Moir, H. Montgomery, and R. J. M. Ross Membrane Reinsertion of a Myristoyl-Peptidyl Anchored Extracellular Domain Growth Hormone Receptor Endocrinology, February 1, 2007; 148(2): 824 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, Z. Rhani, and C. G. Goodyer Characterization of Growth Hormone Receptor Messenger Ribonucleic Acid Variants in Human Adipocytes J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1901 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Lacroix, J. Guibourdenche, T. Fournier, I. Laurendeau, A. Igout, V. Goffin, J. Pantel, V. Tsatsaris, and D. Evain-Brion Stimulation of Human Trophoblast Invasion by Placental Growth Hormone Endocrinology, May 1, 2005; 146(5): 2434 - 2444. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iida, J. P. del Rincon, D.-S. Kim, E. Itoh, K. T. Coschigano, J. J. Kopchick, and M. O. Thorner Regulation of full-length and truncated growth hormone (GH) receptor by GH in tissues of lit/lit or bovine GH transgenic mice Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E566 - E573. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Leung, N. Doyle, M. Ballesteros, K. Sjogren, C. K. W. Watts, T. H. Low, G. M. Leong, R. J. M. Ross, and K. K. Y. Ho Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2 PNAS, February 4, 2003; 100(3): 1016 - 1021. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Goodyer, R. M. O. Figueiredo, S. Krackovitch, L. De Souza Li, J. A. Manalo, and G. Zogopoulos Characterization of the growth hormone receptor in human dermal fibroblasts and liver during development Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1213 - E1220. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |